Sujata Sajjan, Deepika Savant, Rebecca Thomas, Nina Haghi and Margaret Cho. A Very Rare Case of Esophagitis Due to Nivolumab Immunotherapy.
. 2019; 7(6):97-99. doi: 10.12691/AJMCR-7-6-1
nivolumab, esophagitis, immunotherapy, cancer chemotherapy
This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit
[1] | H. Semper, F. M¨¹hlberg, J. Schulz-Menger, M. Allewelt, C. Groh¨¦, Drug-induced myocarditis after nivolumab treatment in a patient with PDL-1-negative squamous cell carcinoma of the lung, in: Pneumologie, Georg Thieme Verlag KG, 2017: p. P127. |
|
[2] | J. Boike, T. Dejulio, Severe Esophagitis and Gastritis from Nivolumab Therapy, ACG Case Rep J. 4 (2017) e57. |
|
[3] | R. Neril, J. Lorton, J. Zonszein, Nivolumab-induced isolated adrenal insufficiency: a case report, AACE Clinical Case Reports. 3 (2016) e210-e212. |
|
[4] | J. Villadolid, A. Amin, Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities, Transl Lung Cancer Res. 4 (2015) 560-575. |
|
[5] | V.A. Boussiotis, Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway, N Engl J Med. 375 (2016) 1767-1778. |
|
[6] | S.L. Topalian, M. Sznol, D.F. McDermott, H.M. Kluger, R.D. Carvajal, W.H. Sharfman, J.R. Brahmer, D.P. Lawrence, M.B. Atkins, J.D. Powderly, P.D. Leming, E.J. Lipson, I. Puzanov, D.C. Smith, J.M. Taube, J.M. Wigginton, G.D. Kollia, A. Gupta, D.M. Pardoll, J.A. Sosman, F.S. Hodi, Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab, J Clin Oncol. 32 (2014) 1020-1030. |
|
[7] | D.E. Dolan, S. Gupta, PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy, Cancer Control. 21 (2014) 231-237. |
|
[8] | J. Naidoo, D.B. Page, B.T. Li, L.C. Connell, K. Schindler, M.E. Lacouture, M.A. Postow, J.D. Wolchok, Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies, Ann. Oncol. 26 (2015) 2375-2391. |
|
[9] | J.H. Chen, M.K. Pezhouh, G.Y. Lauwers, R. Masia, Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies, Am. J. Surg. Pathol. 41 (2017) 643-654. |
|
[10] | F.K. Akarca, O. Can, S. Yalcinli, Y.A. Altunci, Nivolumab, a new immunomodulatory drug, a new adverse effect; adrenal crisis, Turk J Emerg Med. 17 (2017) 157-159. |
|
[11] | M.A. Postow, Managing immune checkpoint-blocking antibody side effects, Am Soc Clin Oncol Educ Book. (2015) 76-83. |
|